Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

873
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
873
Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

687
Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
687
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Tumor Progression02:07

Tumor Progression

6.5K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Retraction Note: NSD2 targeting reverses plasticity and drug resistance in prostate cancer.

Nature·2026
Same author

TMPRSS2-ERG confers resistance of prostate cancer to antiandrogens.

EMBO molecular medicine·2026
Same author

HLA Class I Expression is Associated with Increased Immune Cell Density and PTEN Loss in Prostate Cancer.

Molecular cancer research : MCR·2026
Same author

Evaluation of Tissue from Patients with Prostate Cancer Identifies B7-H3 as an Androgen-Regulated, Broadly-Expressed, Combinatorial Therapeutic Target.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Postdiagnostic Inflammatory and Insulinemic Diet and Lifestyle Patterns and Risk of Prostate Cancer-specific Mortality in the Health Professionals Follow-up Study.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology·2026
Same author

Polygenic risk score and 20-year prostate cancer-specific mortality and survival.

Communications medicine·2026

Related Experiment Video

Updated: Sep 12, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.3K

Tumor Cholesterol Synthesis, Statin Use, and Lethal Prostate Cancer.

Sinead Flanagan1,2, Rosina T Lis3, Ying Huang4

  • 1Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.

Molecular Cancer Research : MCR
|August 5, 2025
PubMed
Summary
This summary is machine-generated.

High expression of 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase (HMGCR) in prostate tumors is linked to increased risk of lethal cancer. This suggests HMGCR may be a target for new prostate cancer therapies.

More Related Videos

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells
09:34

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells

Published on: February 9, 2019

9.1K
MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

11.3K

Related Experiment Videos

Last Updated: Sep 12, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.3K
Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells
09:34

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells

Published on: February 9, 2019

9.1K
MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

11.3K

Area of Science:

  • Oncology
  • Biochemistry
  • Molecular Biology

Background:

  • Prostate tumor cells synthesize cholesterol de novo.
  • Statin therapy targets 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase (HMGCR), a key enzyme in cholesterol synthesis.
  • The role of HMGCR expression in prostate cancer progression and response to statins is not fully understood.

Purpose of the Study:

  • To investigate the association between HMGCR expression in prostate tumors and cancer lethality.
  • To explore the relationship between HMGCR expression, PTEN loss, and tumor aggressiveness.
  • To evaluate the in vitro effect of statins on prostate cancer cells with altered HMGCR levels.

Main Methods:

  • Prospective cohort study of 1098 men diagnosed with primary prostate cancer.
  • Analysis of HMGCR protein expression in tumor tissue.
  • Follow-up for lethal events (metastases, cancer-related death) over up to 32 years.
  • In vitro experiments using LNCaP human prostate cancer cell line.

Main Results:

  • 16% of tumors showed strong HMGCR staining; 31% showed no staining.
  • Strong HMGCR expression was associated with a 2.2-fold increased risk of lethal prostate cancer.
  • HMGCR expression was higher in tumors with PTEN loss.
  • Atorvastatin reduced viability in prostate cancer cells with experimentally lowered HMGCR.

Conclusions:

  • High HMGCR expression in prostate tumors correlates with aggressive characteristics and increased risk of lethality.
  • HMGCR expression is associated with PTEN loss, suggesting a link between cholesterol synthesis and tumor suppressor pathways.
  • These findings highlight HMGCR as a potential therapeutic target for aggressive prostate cancer.